Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Building on its unique position and experience in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. In R&D, Grünenthal executes a concise therapeutic area strategy, drawing from a wide range of modalities.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2018, Grünenthal employed around 4,900 people and achieved sales of € 1.3 bn.
Our contribution to the project
Grünenthal Group
